SGI-DNA Launches Gibson Assembly® Site-Directed Mutagenesis Kit for Accurate, Robust and Efficient Site-directed Mutagenesis of DNA Fragments

(LA JOLLA, CA) September 1, 2015, 2015- SGI-DNA, a Synthetic Genomics, Inc. company announces the launch of the Gibson Assembly® Site-Directed Mutagenesis Kit which allows researchers to efficiently and accurately perform site-directed mutagenesis on DNA fragments. This kit is the third in SGI-DNA’s Gibson Assembly® portfolio, which empowers life science researchers to substantially increase their ability to build genes, edit them, and study their functions using nucleotide insertions, substitutions, or deletions. The Gibson Assembly® Site-Directed Mutagenesis Kit has been optimized to maximize the number of gene editing studies scientists can perform, as it uses less DNA starting material, accommodates larger DNA fragments, and has a higher efficiency compared to existing kits. More information about SGI-DNA’s Gibson Assembly® kit and reagent portfolio can be found at sgidna.com/gibson-assembly.

The Gibson Assembly® method was developed in 2009 by Daniel Gibson and his colleagues at the J. Craig Venter Institute during the team’s quest to construct the first synthetic cell. Since its introduction to the life science community, the Gibson Assembly® method has become a mainstay in many synthetic biology laboratories and has attracted interest from both the academic and commercial life sciences community due to its ease-of-use, robustness, and flexibility. The Gibson Assembly® Site-Directed Mutagenesis Kit complements the Gibson Assembly® HiFi 1-Step Kit and the Gibson Assembly® Ultra Kit, which have been developed and optimized for robust DNA assembly by SGI-DNA in close collaboration with Daniel Gibson’s research group at Synthetic Genomics.

“I’m pleased that the DNA assembly technologies we developed to build the first synthetic cell can now be used by other scientists to study genes, families, and pathways more completely,” said Dan Gibson. “Molecular biologists can now greatly advance their genomics research by increasing their capacity to study the activities of genes and proteins.”

Starting with a circular or a linear DNA template up to 25 kilobases in length, scientists can now introduce up to 5 site directed mutations in a single round. The Gibson Assembly® Site-Directed Mutagenesis Kit enables researchers to accommodate one or up to five site mutations with efficiencies of 95% and 55% respectively. Only 5 nanograms of DNA starting material is needed with this kit, compared to other commercially available kits that require up to 100 nanograms of DNA. The Gibson Assembly® Site-Directed Mutagenesis Kit is available in 2 sizes: 5 reactions (starter kit) and 10 reactions.

For more information on the Gibson Assembly® Site-Directed Mutagenesis Kit, please visit www.sgidna.com/sdm-kit

All products are intended for research use only. Not intended for diagnostic uses.

The Gibson Assembly® method is also available under commercial license. For more information contact us at info@sgidna.com

About SGI-DNA

SGI-DNA, a wholly owned subsidiary of Synthetic Genomics, Inc (SGI), is responsible for all commercial aspects of SGI’s synthetic DNA business and focuses on strategic business relationships with both academic and commercial researchers. Building on the scientific advancements and breakthroughs from leading scientists such as J. Craig Venter, Ham Smith, Clyde Hutchison, Dan Gibson and their teams, SGI-DNA utilizes unique and proprietary DNA technologies to produce complex synthetic genes and reagents. SGI-DNA also offers a comprehensive suite of genomic services, including whole genome sequencing, library design, and other bioinformatics services.

Media Contact

Mary Canady, 858-433-4994, mcanady@syntheticgenomics.com

SGI-DNA Receives Frost & Sullivan 2015 North American Synthetic Biology New Product Innovation Award for the BioXp™ 3200 System

(LA JOLLA, Calif.) – August 4, 2015 – SGI-DNA, a Synthetic Genomics, Inc. (SGI) company, was recently recognized by Frost & Sullivan for its groundbreaking innovation in genomic technologies for the BioXp™ 3200 System,  an instrument with the capacity to simultaneously build 32 unique, double-stranded DNA fragments to study gene function, pathways, and whole genomes. Frost & Sullivan, leveraging over 50 years of experience in partnering with Global 1000 companies, evaluated the BioXp™ System’s new product attributes and customer impact, and awarded SGI-DNA its 2015 North American Synthetic Biology New Product Innovation Award at a ceremony July 16, 2015, in Boston, Mass.

SGI-DNA, a wholly owned subsidiary of SGI, is commercializing technologies, reagents, software, and services around synthetic biology. Founded in 2013 and headquartered in La Jolla, Calif., SGI-DNA commercializes the technologies developed through SGI’s core research and development efforts. Synthetic Genomics is making advancements in various scientific applications, such as vaccine development, agricultural biology, organ transplantation, and alternative food, energy  and chemical source development.

One technology to emerge is the recently launched BioXp™ System, an automated DNA assembly benchtop instrument. The platform fully automates DNA assembly, building genes de novo from sequences. This first-of-its-kind instrument will allow researchers to perform their own gene assembly in-house, a task that previously required outsourcing to services providers. By performing the work in-house, laboratories are able to speed up the workflow, control their project timelines, and ensure the highest accuracy of their DNA constructs. Fully automated, the BioXp™ System provides a simple push-button walk-away workflow, allowing users to focus time and energy on other tasks, and run the instrument overnight.

“SGI-DNA’s BioXp™ 3200 System is a major milestone in the synthetic biology field, allowing users to perform DNA assembly quickly and easily in-house, a task that previously required outsourcing,” stated Frost & Sullivan Senior Industry Analyst Christi Bird. “This innovative instrument will help the biotechnology sector and other labs conducting synthetic biology-based projects to speed up and improve their workflows, leading to faster scientific advancements in their fields. For these reasons, SGI is the ideal recipient of the Frost & Sullivan New Product Innovation Award.”

The award ceremony also included Cisco, GE Healthcare, and IBM Security. Laurence Warden, SGI-DNA’s Vice President, Engineering and Instrumentation, and Nathan Wood, Senior Vice President, Synthetic Genomics & President, SGI-DNA, accepted the award. The SGI-DNA BioXp™ System team has achieved many milestones in 2015, including the manufacture and  installation of multiple instruments for early access customers, including biotechnology companies, government laboratories, and research institutions.

“We are honored to have been recognized for new product innovation by Frost & Sullivan,” said Warden. “This award is very gratifying for the team, who designed the BioXp™ System to match the vision of scientific thought leaders at SGI to provide entirely new and improved workflows for biomedical researchers.”

About SGI-DNA

SGI-DNA, a wholly owned subsidiary of Synthetic Genomics, Inc (SGI), is responsible for all commercial aspects of SGI’s synthetic DNA business and focuses on strategic business relationships with both academic and commercial researchers. Building on the scientific advancements and breakthroughs from leading scientists such as J. Craig Venter, Hamilton Smith, Clyde Hutchison, Daniel Gibson and their teams, SGI-DNA utilizes unique and proprietary DNA technologies to produce complex synthetic genes and reagents. SGI-DNA also offers a comprehensive suite of genomic services, including whole genome sequencing, library design, and other bioinformatics services.

Media Contact

Mary Canady, 858-433-4994, mcanady@syntheticgenomics.com

Synthetic Genomics and Gen9 Sign Licensing Agreement for Synthetic Biology Technology Patents

(LA JOLLA, CA and CAMBRIDGE, MA)–June 11, 2015 – Synthetic Genomics Inc. (SGI), a synthetic biology company advancing and innovating genomic science and technologies for transformative products and solutions, and Gen9 Inc., a pioneer in synthetic biology and leader in the development of scalable technologies for synthesizing and assembling DNA, today announced a strategic licensing agreement to leverage their respective strengths in synthetic biology technology development and commercialization. The agreement provides Gen9 Inc. with a non-exclusive worldwide license to SGI’s Febit intellectual property estate. The financial details of the agreement were not disclosed.

In 2012, SGI purchased from Febit Holding GmbH the worldwide rights to three families of patents and patent applications related to key synthetic genomic technologies. All related know-how, equipment and technical support for implementation, were also purchased. This technology included methods for highly parallelized, low-cost oligonucleotide synthesis and retrieval of sequence-validated DNA.  SGI has been using the Febit technology internally in development of key gene synthesis applications.

“We see great value in the Febit IP for companies like Gen9 to increase efficiencies in their manufacturing platforms for the benefit of their customers,” said Nathan Wood, Synthetic Genomics Senior Vice President and President of SGI-DNA, Reagents and Instruments. “We look forward to working with Gen9 and with other companies who are interested in licensing this important family of synthetic biology technology patents.”

“We are excited to announce this agreement with Synthetic Genomics.  As we continue to develop novel applications that leverage our BioFab® platform, we are always seeking to identify new technologies and collaborate with innovative partners in the synthetic biology field,” said Kevin Munnelly, President and CEO of Gen9.

About Synthetic Genomics Inc. (SGI)

SGI is a privately-held company dedicated to developing and commercializing genomic-driven solutions to address a wide range of global challenges. The company is focused on several key commercialization programs including developing new synthetic DNA products, tools and instruments through its subsidiary, SGI-DNA; new and improved algae based food and nutritional products, and biofuels through its subsidiary Genovia Bio; and synthetically-derived vaccines and anti-microbials through Synthetic Genomic Vaccines Inc. (SGVI), a business unit co-founded with the J. Craig Venter Institute. The company is also developing clean water technologies using microbial fuel cells and is developing sustainable agricultural products through AgraCast, a company co-founded with Plenus S.A. de C.V.  For more information go to: www.syntheticgenomics.com

About Gen9

Gen9 is the premier next-generation gene synthesis company focused on high-quality, high-throughput, automated production of DNA constructs. The Gen9 technology allows for the lowest-cost and highest-quality DNA constructs commercially available. Founded by world leaders in synthetic biology, Gen9 aims to ensure the constructive application of synthetic biology in industries ranging from enzyme and chemical production to pharmaceuticals and biofuels. Gen9 is powering the synthetic biology revolution from our headquarters in Cambridge, Massachusetts. Visit Gen9 at www.gen9bio.com.
Gen9, GeneBit, GeneByte and BioFab are trademarks or registered trademarks of Gen9, Inc. All other brands may be trademarks of their respective holders.

Media Contacts

SGI: Heather Kowalski, 858-361-0466, hkowalski@syntheticgenomics.com
SGI-DNA: Mary Canady, 858-433-4994, mcanady@syntheticgenomics.com
Gen9: Colin Sanford, 203-918-4347, colin@bioscribe.com

International Gene Synthesis Consortium Forms Not-for-Profit Corporation

New Organizational Structure Will Enable a Diverse Set of Stakeholders to Leverage the IGSC’s Biosecurity Expertise

(MENLO PARK, CA) April 28, 2015 –The International Gene Synthesis Consortium (IGSC), an association of the world’s leading gene synthesis companies, today announced that it has established itself as a not-for-profit U.S. corporation. The move is intended to make it easier for the organization to welcome new members, especially small companies, not-for-profits and academic institutions, so that they may leverage the biosecurity expertise of the IGSC.

Working together with governments, NGOs, law enforcement, the synthetic biology community and other stakeholders, the IGSC aims to safeguard biosecurity and promote the beneficial application of gene synthesis technology. By screening the sequences of ordered genes and vetting customers, IGSC members help to ensure that science and industry realize the many benefits of gene synthesis technology while minimizing risk.

“The IGSC has developed a common protocol for biosecurity screening and devotes resources to leading-edge development of best practices,” said Todd Peterson, Chief Technology Officer of Synthetic Genomics Inc. and current Board Chair of the IGSC. “By establishing a more formal structure for the IGSC, we hope to encourage organizations involved in gene synthesis across the globe to benefit from the biosecurity expertise of our membership.”

The IGSC encourages other gene synthesis companies and institutions with common biosecurity goals to join. IGSC Voting Membership is available to gene synthesis companies while Associate Membership is available to smaller companies, not-for-profit entities and academic institutions.

“The IGSC takes pride in leading the way on biosecurity practice and innovation in the field,” said Tim Conlon, Assistant General Counsel, Capital Markets and International for Integrated DNA Technologies, Inc. and current IGSC Secretary. “A strong investment in strong biosecurity practice now will help to ensure the safe growth of an industry that holds the keys to important technological advances in the coming decades.”

About IGSC

The IGSC was founded in 2009 by the world’s leading gene synthesis companies to advance biosecurity across the industry. The IGSC’s goals are (a) to educate gene synthesis companies and the public regarding sequence and customer screening of synthetic gene orders; (b) to identify and prevent the unauthorized synthesis and sale of inappropriate sequences; and (c) to coordinate development of ongoing best practices. For more information about membership or the IGSC screening process, please visit www.genesynthesisconsortium.org.

# # #

Media Contact

Heather Kowalski: hkowalski@syntheticgenomics.com, 858-361-0466

SGI-DNA Launches the BioXp™ 3200 System Early Access Program

BioXp™ System Provides Scientists with Ability to Create High Quality, Synthetic DNA Fragments; Key to Constructing Synthetic Genes, Gene Pathways and Whole Genomes

(LA JOLLA, CA) April 02, 2015 – SGI-DNA Inc. today announced the launch of the BioXp™ 3200 System Early Access Program giving researchers priority access to this one of a kind, personal DNA work station which delivers high quality synthetic DNA fragments. The BioXp™ Instrument has the capacity to simultaneously build 32 unique double-stranded DNA fragments. It is the first instrument system of its kind and empowers researchers with the ability to produce high quality synthetic DNA fragments virtually hands free.

Daniel Gibson, Ph.D., VP DNA Technology at Synthetic Genomics, Inc. states, “The vision is to evolve this system with greater capabilities by continuing to develop downstream applications for synthetic biology. Over time, the BioXp™ System will allow researchers to focus on experimental design instead of performing many of the tedious tasks of cloning and expression.”

In addition to the opportunity to significantly advance their synthetic biology research, Early Access Program customers will enjoy exclusive perks such as an enhanced level of technical and customer support, including priority treatment of obtaining their constructs whether provided via BioXp™ DNA Assembly reagents or through SGI-DNA’s custom synthesis service that excels in synthesizing long and difficult constructs.

The BioXp™ system utilizes the Gibson Assembly® technology and is coupled with a unique error correction formulation resulting in the synthesis of highly accurate DNA fragments. DNA fragments are ready for many applications including off-line sequencing, cloning, assembly into larger fragments, and expression into RNA and proteins. SGI-DNA’s custom gene synthesis service option provides synthesis of longer and more challenging constructs for all gene synthesis needs for customers.

The Gibson Assembly® method was developed in 2009 by Daniel Gibson, Ph.D., and his colleagues at the J. Craig Venter Institute during the team’s quest to construct the first synthetic cell. Since its introduction to the life science community, the Gibson Assembly® method has become a mainstay in many synthetic biology laboratories and has attracted interest from both the academic and commercial life sciences community due to its ease-of-use, robustness, and flexibility.

For more information on the BioXp™ 3200 System, please visit www.sgidna.com/bxp3200. You may also email your request to info@sgidna.com. SGIDNA is a member of the International Gene Synthesis Consortium. All products are for research use only and are not intended for diagnostic uses.

About SGI-DNA

SGI-DNA, a wholly owned subsidiary of Synthetic Genomics, Inc. (SGI), is responsible for all commercial aspects of SGI’s synthetic DNA business and focuses on strategic business relationships with both academic and commercial researchers. Building on the scientific advancements and breakthroughs from leading scientists such as J. Craig Venter, Hamilton Smith, Clyde Hutchison, Dan Gibson and their teams, SGI-DNA utilizes unique and proprietary DNA technologies to produce complex synthetic genes and reagents. SGI-DNA also offers a comprehensive suite of genomic services, including whole genome sequencing, library design, and other bioinformatics services.

# # #

Media Contact

Heather Kowalski: hkowalski@syntheticgenomics.com, 858-361-0466

SGI-DNA Launches Gibson Assembly® Ultra Kit for Robust, Seamless and Efficient Construction of Synthetic Genes, Genetic Pathways and Whole Genomes

(LA JOLLA, CA) January 21, 2015–SGI-DNA announces the launch of the Gibson Assembly® Ultra Kit which allows researchers to perform complex, large, and multiple fragment assemblies in a simple, two-step reaction.

“With the Gibson Assembly® Ultra Kit, researchers can assemble up to 15 fragments at one time in less than two hours,” says Vibhu Gupta, Senior Product Manager at Synthetic Genomics, Inc. “The kit provides a proprietary enzyme formulation for Gibson Assembly®, allowing researchers to assemble fragments ranging from 100 bp to 100 kb.” “Our goal is to provide researchers with cutting-edge, easy to use, and seamless technology that takes synthetic biology to a whole new level.”

This Gibson Assembly® Ultra Kit is the second kit in SGI’s growing Gibson Assembly® portfolio utilizing the Gibson Assembly® method. The first kit launched was the Gibson Assembly® HiFi 1 Step Kit, a high fidelity formulation that significantly reduces errors/mutations at the cloning junctions, enabling researchers to assemble up to 5 fragments in a one hour, one-step reaction.

The Gibson Assembly® method was developed in 2009 by Dan Gibson, Ph.D., and his colleagues at the J. Craig Venter Institute during the team’s quest to construct the first synthetic cell. Since its introduction to the life science community, the Gibson Assembly® method has become a mainstay in many synthetic biology laboratories and has attracted interest from both the academic and commercial life sciences community due to its ease-of-use, robustness, and flexibility.

The Gibson Assembly® Ultra Kit is available in 3 sizes: 5 reactions (starter kit), 10 reactions and 50 reactions. Mastermixes are sold separately.

For more information on the Gibson Assembly® Ultra Kit, please visit www.sgidna.com/ultra_kit

For more information on the Gibson Assembly® HiFi 1 Step Kit, please visit www.sgidna.com/hifi_kit

All products are for research use only and are not intended for diagnostic uses.

The Gibson Assembly® method is also available under commercial license. For more information contact us at info@sgidna.com

About SGI-DNA

SGI-DNA, a wholly owned subsidiary of Synthetic Genomics, Inc (SGI), is responsible for all commercial aspects of SGI’s synthetic DNA business and focuses on strategic business relationships with both academic and commercial researchers. Building on the scientific advancements and breakthroughs from leading scientists such as J. Craig Venter, Ham Smith, Clyde Hutchison, Dan Gibson and their teams, SGI-DNA utilizes unique and proprietary DNA technologies to produce complex synthetic genes and reagents. SGI-DNA also offers a comprehensive suite of genomic services, including whole genome sequencing, library design, and other bioinformatics services.

# # #

Technical Contact

Vibhu Gupta: vgupta@syntheticgenomics.com, 858-433-2288

Media Contact

Heather Kowalski: hkowalski@syntheticgenomics.com, 858-361-0466

SGI-DNA Launches Gibson Assembly® HiFi 1 Step Kit for Simple, Seamless and Rapid Construction of Synthetic Genes, Gene Clusters and Genetic Pathways

LA JOLLA, Calif., Nov. 20, 2014 — SGI-DNA announces the launch of the Gibson Assembly® HiFi 1 Step Kit which allows researchers to assemble multiple, large DNA fragments in a simple one hour, one-step reaction.

This is the first high fidelity kit on the market using the Gibson Assembly® method.  Researchers can now assemble up to 5 fragments, including large constructs (up to 100 kb), in a fast, reliable reaction.

“With the Gibson Assembly® HiFi 1 Step Kit researchers can obtain a perfect clone in their initial attempt,” says Vibhu Gupta, Senior Product Manager at SGI-DNA. “The kit provides a proprietary enzyme formulation for Gibson Assembly® that results in significantly less errors at cloning junctions which is a common challenge for researchers in a variety of disciplines.”

A researcher from the University of California, San Diego, Erna van Niekerk, PhD., comments, “I have tried it with a construct and ran a parallel experiment with a competing kit from another vendor. I picked 3 colonies from the Gibson Assembly® HiFi 1 Step Kit and 3 colonies from the competing product. Three of 3 Gibson clones gave me the right insert. Zero of 3 from competing kit gave me the right insert. Of the 3 Gibson clones: 2 of 3 had the correct sequence both forward and reverse sequencing confirmation and 1 of 3 had an extra nucleotide.”

The Gibson Assembly® method was developed in 2009 by Dan Gibson, Ph.D., and his colleagues at the J. Craig Venter Institute during the team’s quest to construct the first synthetic cell. It uses a one-step, isothermal approach to enable the rapid assembly of oligonucleotides and multiple DNA fragments. Since its introduction to the life science community, the Gibson Assembly® method has become a mainstay in many synthetic biology laboratories and has attracted interest from both the academic and commercial life sciences community due to its ease-of-use, robustness and flexibility. This Gibson Assembly® kit provides researchers SGI’s first commercially available option utilizing the Gibson Assembly® method.

The Gibson Assembly® HiFi 1 Step Kit is available in 3 sizes: 5 reactions (starter kit), 10 reactions and 50 reactions.

For more information on the Gibson Assembly® HiFi 1 Step Kit, please visit www.sgidna.com

All products are intended for research use only. Not intended for diagnostic uses.

The Gibson Assembly® method is also available under commercial license. For more information contact us at info@sgidna.com

About SGI-DNA

SGI-DNA, a wholly owned subsidiary of Synthetic Genomics, Inc (SGI), is responsible for all commercial aspects of SGI’s synthetic DNA business and focuses on strategic business relationships with both academic and commercial researchers. Building on the scientific advancements and breakthroughs from leading scientists such as J. Craig Venter, Ham Smith, Clyde Hutchison, Dan Gibson and their teams, SGI-DNA utilizes unique and proprietary DNA technologies to produce complex synthetic genes and reagents. SGI-DNA also offers a comprehensive suite of genomic services, including whole genome sequencing, library design, and other bioinformatics services.

SGI-DNA Technical contact: Vibhu Gupta, Senior Product Manager, 858.433.2288; vgupta@syntheticgenomics.com

Media contact: Heather Kowalski, hkowalski@syntheticgenomics.com; 858-361-0466

Synthetic Genomics Inc. Appoints Oliver Fetzer, Ph.D., MBA as Chief Executive Officer

J. Craig Venter, Ph.D., Co-founder and Former CEO, becomes Executive Chairman and Co-Chief Scientist

(LA JOLLA, CA) October 27, 2014- Synthetic Genomics, Inc. (SGI), a synthetic biology company commercializing genomic technologies to revolutionize several industries, today announced the appointment of Oliver Fetzer, Ph.D., MBA as the company’s new Chief Executive Officer (CEO). In his role as CEO Fetzer will also be a member of SGI’s Board of Directors. Founding CEO, J. Craig Venter, Ph.D., will remain actively involved in SGI as Executive Chairman and Co-Chief Scientist with Co-Founder, Hamilton Smith, M.D.

“I am excited to welcome Oliver as the new CEO of SGI,” said Dr. Venter. “His decades of proven biotechnology product development experience coupled with his scientific intellect and measured leadership style will help drive SGI’s continued upward trajectory. I look forward to working with Oliver and the executive team to continue to meet our goals of turning SGI’s science and technology into commercially viable and societal changing products.”

Dr. Venter is also Co-Founder and CEO of the company Human Longevity, Inc., and Founder, Chairman and CEO of the not-for-profit J. Craig Venter Institute.

“I am thrilled to become the CEO of Synthetic Genomics, a company that unites leading science with a strong platform to address some of the world’s pressing needs, and a proven track record of applying these capabilities in high profile partnerships,” said Dr. Fetzer. “I look forward to working with Craig and an exceptional team to fulfill SGI’s vision and to advance the company into commercialization.”

Dr. Fetzer will lead all aspects of SGI, including management of SGI’s three business units- SGI-DNA, Synthetic Genomics Vaccines, Inc. (SGVI), and Genovia Bio. Over the last several years, SGI has refined its business plan to leverage and deploy its core synthetic biology technologies in a variety of industries. One of the most important recent announcements for the company is the agreement with Lung Biotechnology, a subsidiary of United Therapeutics Corporation, to create humanized pig organs for transplantation. SGI has also expanded its algae programs to include important deals with Archer Daniels Midland Company in the Omega-3 nutritional products sector.

Dr. Fetzer comes to SGI from Cerulean Pharma Inc., a pharmaceutical company that develops nanoparticle drug conjugate oncology therapeutics, where he was President and CEO for five years. Under Dr. Fetzer’s leadership, Cerulean advanced from a pre-clinical platform company to become a publicly traded clinical development stage company with a pipeline of product candidates.

Prior to Cerulean Pharma, Dr. Fetzer served in variety of positions at Cubist Pharmaceuticals, Inc., including Senior Vice President, Corporate Development and Research & Development, Senior Vice President, Corporate Development and Chief Business Officer, and Senior Vice President, Business Development. Dr. Fetzer began his career in 1993 in various positions of increasing responsibility at the Boston Consulting Group (BCG), a global leading management consulting firm, including Consultant, Project Leader, Principal, Partner and Managing Director. Since 2005, Dr. Fetzer has served on the board of directors of Auxilium Pharmaceuticals, Inc., and since 2011, on the board of Tecan Group AG.

Dr. Fetzer received a B.S. in Biochemistry from the College of Charleston, his Ph.D. in Pharmaceutical Sciences from the Medical University of South Carolina, and an MBA from Carnegie Mellon University.

About Synthetic Genomics Inc. (SGI)

SGI is a privately-held company dedicated to developing and commercializing genomic-driven solutions to address a wide range of global challenges. The company is focused on several key commercialization programs including developing new synthetic DNA products, tools and instruments through its subsidiary, SGI-DNA; new and improved algae based food and nutritional products, and biofuels through its subsidiary Genovia Bio; and synthetically-derived vaccines and anti-microbials through Synthetic Genomic Vaccines Inc. (SGVI), a business unit co-founded with the J. Craig Venter Institute. The company is also developing clean water technologies using microbial fuel cells and is developing sustainable agricultural products through AgraCast, a company co-founded with Plenus S.A. de C.V. For more information go to: www.syntheticgenomics.com.

SGI Media Contact

Heather Kowalski
858-361-0466
hkowalski@syntheticgenomics.com

Avoca Signs Supply Agreement with Synthetic Genomics Inc to Become Domestic Source of Natural Astaxanthin

KEARNY, NJ and LA JOLLA, CA, JUNE 20, 2014 – Avoca, Inc., a division of Pharmachem Laboratories, Inc., has formed a supply agreement with Synthetic Genomics, Inc. (SGI), a privately held company developing and commercializing genomic driven solutions and products in a variety of industries, to extract and commercialize natural astaxanthin from a strain of algae developed by SGI. The multi-year supply agreement also provides Avoca with exclusivity for product sales in North America. Pharmachem Laboratories will be responsible for marketing and sales. SGI is developing this product through their Genovia Bio business unit, which is responsible for the development and commercialization of algal-based food, chemical and fuel products. Financial details were not disclosed.

According to David Peele, President of Avoca, “This agreement will make us one of just a handful of vertically integrated, domestic producers of astaxanthin, with SGI providing sufficient algae biomass to ensure our customers of a consistent supply from U.S. sources,” said Peele. “Using their proprietary technology, SGI has developed algae with a higher level of astaxanthin, and as a result, we can provide 7.5% astaxanthin oleoresin with the concentration increasing over time as the algae strain and production technology is improved.”

“We are very pleased to enter into this agreement with Avoca,” said Jon Getzinger, Sr. Vice President, SGI. “Our ability to develop advantaged nutraceutical and human and animal feed ingredients coupled with Avoca’s ability to process and market those products, makes this an ideal agreement for both companies. Commercialization of astaxanthin with Avoca demonstrates how we can supply important high quality, natural ingredients to the market using our algae technology,” said Getzinger.

Natural astaxanthin is a supplement with multiple clinically-proven health benefits associated with its powerful antioxidant and anti-inflammatory properties. Natural astaxanthin is very difficult to produce and therefore is supply constrained relative to demand. SGI has developed a process for production of natural astaxanthin from a phototrophic source and demonstrated commercial-scale manufacturing capability and performance over 18 months. SGI’s natural astaxanthin has U.S. Food and Drug Administration regulatory approval for dietary supplement applications.

“We looked at several companies to partner with on this important ingredient,” said Jim Flatt, President of SGI’s Genovia Bio. “Avoca is the strong partner we sought who was capable of both processing high quality oil and delivering the product to the market through Pharmachem’s professional sales and marketing organization. Genovia Bio has rapidly developed two commercially-ready products, one each from heterotrophic (sugar-utilizing) and phototrophic (light-utilizing) algae, which distinguishes Genovia Bio in this field. It’s exciting to see the pipeline of products emerging from our investment in algae product technology.”

About Synthetic Genomics Inc. (SGI)

SGI is a privately-held company dedicated to developing and commercializing genomic-driven solutions to address a wide range of global challenges. The company is focused on several key commercialization programs including: developing new synthetic DNA products and technologies through its subsidiary, SGI-DNA; algae biofuels and new and improved food and nutritional products through its subsidiary Genovia Bio; and synthetically-derived vaccine development through Synthetic Genomic Vaccines Inc. (SGVI), a business unit co-founded with the J. Craig Venter Institute. The company is also developing clean water technologies using microbial fuel cells and is developing sustainable agricultural products through AgraCast, a company co-founded with Plenus S.A. de C.V. For more information go to www.syntheticgenomics.com.

About Pharmachem Laboratories, Inc.

Pharmachem Laboratories, Inc., Kearny, NJ, is a family of companies specializing in the manufacture and supply of a wide variety of custom and specialty nutritional ingredients, as well as process services. The company is a NOP-Certified organic handler and processor, operating 16 manufacturing facilities in the U.S. and Mexico. It is also (c)GMP compliant, producing a variety of ingredients and ingredient systems under strict quality control. For further information call 800-526-0609, 201-246-1000 (outside the U.S.) or visit www.pharmachemlabs.com.

Media Contact for SGI

Heather Kowalski
858-361-0466
hkowalski@syntheticgenomics.com

Technical/Scientific
Jon Getzinger
858-754-2960
jgetzinger@syntheticgenomics.com

Media Contact for Avoca

Tom McCartney
412-361-5178
tmcom@verizon.net

Synthetic Genomics Inc. and ADM Announce Omega-3 DHA Strategic Partnership

LA JOLLA, Calif. and DECATUR, Ill, May 19, 2014 – Synthetic Genomics Inc. (SGI), a privately held company developing and commercializing genomic driven advancements in a variety of industries, and Archer Daniels Midland Company (NYSE: ADM) announced today that the two companies have entered into a long-term agreement to commercialize Omega-3 Docosahexaenoic Acid (DHA) from algae. As part of the agreement, Omega-3 DHA will be produced and marketed throughout the world by ADM’s Foods & Wellness and Animal Nutrition groups. Financial details of the deal were not disclosed.

DHA is a long-chain omega-3 fatty acid that has been studied for its role in brain, heart and eye health. While it is typically found in fish and seafood products, extracting DHA directly from algae grown in fermentation tanks yields a highly purified form of DHA, which can then be used as a dietary supplement for humans and in animal feed.

“We are pleased to be working with ADM, a global leader in human and animal health and nutrition,” said J. Craig Venter, Founder and CEO, SGI. “This agreement is a major accomplishment for SGI as it represents commercial validation of our science and technology. We are eager to continue to work with ADM to develop other unique and nutritionally sound food and nutraceutical ingredients.”

“This partnership is an important example of ADM’s ongoing efforts to enhance returns by strengthening our portfolio of higher-margin products,” said Greg Dodson, general manager, ADM Foods & Wellness. “There is significant demand for Omega-3 DHA products. We are impressed with the leading edge technologies that SGI uses to quickly turn commercial opportunities into realities, and we look forward to working with them to use those capabilities to further enhance our current portfolio of nutritional ingredients.”

“The ADM partnership with SGI will prove beneficial for both companies by capitalizing on the strengths of SGI’s technologies and know-how, while using ADM’s significant scale and production capabilities to commercialize important products demanded by our customers,” said Brent Fenton, president, ADM Animal Nutrition. “The end result will be an improved animal nutrition portfolio, which will deliver value both to our customers and our shareholders.”

“We are excited to have this partnership with ADM that will allow them to provide a real alternative to what had been a very short list of non-fish derived DHA ingredients,” said Jon Getzinger, senior vice president at SGI. “Having a real choice in the market will provide manufacturers the opportunity for broader inclusion of this essential nutrient in food, beverage, nutraceutical and animal feed applications.”

The program will be done by SGI’s Genovia Bio business unit, leading producers of algal bio-based food, chemical, and fuel products. The team designs, develops, manufactures and enables others to manufacture nutritional and personal care ingredients, chemicals and fuels through low-cost, sustainable bio-based production methods from renewable feedstocks, including sugar, and carbon dioxide and sunlight. The business unit also licenses technology to strategic partners to manufacture higher-volume products.

Genovia Bio has labs within the SGI offices in La Jolla, California and has a research and development and phototrophic algae production facility in Calipatria, California near the Salton Sea.

About Synthetic Genomics Inc. (SGI)

SGI is a privately-held company dedicated to developing and commercializing genomic-driven solutions to address a wide range of global challenges. The company is focused on several key commercialization programs including: developing new synthetic DNA products and technologies through its subsidiary, SGI-DNA; algae biofuels and new and improved food and nutritional products through its subsidiary Genovia Bio; and synthetically-derived vaccine development through Synthetic Genomic Vaccines Inc. (SGVI), a business unit co-founded with the J. Craig Venter Institute. The company is also developing clean water technologies using microbial fuel cells and is developing sustainable agricultural products through AgraCast, a company co-founded with Plenus S.A. de C.V. For more information go to www.syntheticgenomics.com.

About ADM Foods & Wellness

ADM’s Foods & Wellness group offers a range of innovative specialty ingredients and products for the beverage, meat, snack, bakery, cerdodeal, wellness and personal care markets. As a global market leader in food-grade proteins, ADM’s Foods & Wellness group also markets numerous health and nutrition products, lecithin, acidulants, hydrocolloids and polyols.

About ADM Animal Nutrition

ADM Animal Nutrition is a leading manufacturing, nutrition and marketing company, which offers a wide range of innovative products for the animal nutrition market. Known as a global leader in amino acids, ADM Animal Nutrition also offers consistent, high-quality feed products, supplements, premixes, custom ingredient blends and specialty feed ingredients designed to provide leading-edge solutions, enabling our customers to meet and optimize animal health and nutrition goals.

About ADM

For more than a century, the people of Archer Daniels Midland Company (NYSE: ADM) have transformed crops into products that serve vital needs. Today, 31,000 ADM employees around the globe convert oilseeds, corn, wheat and cocoa into products for food, animal feed, industrial and energy uses. With more than 270 processing plants, 470 crop procurement facilities, and the world’s premier crop transportation network, ADM helps connect the harvest to the home in more than 140 countries. For more information about ADM and its products, visit www.adm.com.

Media Contact for SGI

Heather Kowalski
858-361-0466
hkowalski@syntheticgenomics.com

Media Relations for ADM

Jackie Anderson
217-424-5413
media@adm.com